|
|
|
| Brand | Other Names | Presentation | Strengths | Enquire |
| Litak ® | cladribine | Injection/Infusion | 10 mg / 5 mL; 1 vial |
| TGA indication | |
| LITAK is indicated for the treatment of hairy cell leukaemia and the second line treatment of lymphoplasmacytic lymphoma (Waldenstom's Macroglobulinaemia), i.e. after failure of alkylating agents. | |
| PBS listing | |
Authority required.
Hairy cell leukaemia. | |
| Information for Patients | |
| Consumer Medicine Information | |
| Information for Healthcare Professionals | |
| Product Information | Litak_PI |
